Core Viewpoint - 华检医疗 has signed a strategic cooperation framework agreement with 华大共赢 to establish the "华检华大共赢创新药知识产权代币化基金," aimed at investing in Web3 exchange ecosystem projects in Hong Kong and the US [1][6]. Group 1: Fund Establishment and Market Context - The newly established fund will be managed by 华大共赢, which will act as the general partner, while 华检医疗 will contribute as a limited partner [7]. - The fund's creation coincides with a significant recovery in the innovative drug capital market, with 18 companies in the healthcare sector successfully listing and raising over 18 billion yuan in the first half of the year [7]. - The innovative drug sector has become a hot investment area, with the 中证港股通创新药指数 increasing by over 124% since the beginning of the year [7]. Group 2: Web3 Strategy and Ecosystem - The fund represents a key component of 华检医疗's "NewCo+RWA+stablecoin" strategy, which aims to reshape the global medical innovation drug asset value chain [9]. - 华大共赢 will provide comprehensive services from due diligence to transaction design for selected innovative pharmaceutical companies or target assets [9]. - The ecosystem includes the "IVDNewCo Exchange" trading platform and the proprietary stablecoin IVD Dollar (IVDD), with regulatory applications already initiated in the US and Hong Kong [9][10]. Group 3: Market Potential and Value Chain Reconstruction - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP, with innovative drug asset tokenization having inherent advantages [11]. - The traditional pharmaceutical R&D model faces liquidity issues, with 80% of funding consumed during clinical phases, excluding ordinary investors [11]. - 华检医疗's approach focuses on the medical innovation drug sector, aiming to create a "global free trading market" through its three-tiered structure [11][12]. Group 4: Brand Transformation - 华检医疗 announced a brand upgrade alongside the fund's establishment, redefining its core brand "IVD" to emphasize Innovation, Verification, and Development [13][14]. - The new logo symbolizes the company's vision of enabling top medical innovation drug IP to circulate freely like digital currency [14][15].

Crypto Platform Capabilities - The platform aims to support a wide range of crypto assets and functionalities, including Real World Assets (RWAs), smart contracts, and stablecoins [1] - The platform positions itself as superior to centralized exchanges (CEXs) by supporting decentralized exchanges (DEXs) [1] Metaphorical Description - The platform uses the metaphor of a "shishkabob of crypto" to illustrate its comprehensive support for various crypto elements [1]

RT Morgan Krupetsky (@MorganKrupetsky)Welcoming @grovedotfinance to the Avalanche ecosystem, along with OG RWA platform @centrifuge.I've been especially excited about this partnership for a while. Back when I met @kevinlichan from his days at BlockTower Credit, I remember being struck by our mutual belief in how on-chain ecosystems could truly revolutionize & upgrade legacy financial infrastructure. It's rare to find partners so aligned in that vision.Today, that shared vision culminates in a momentous step ...

Plume’s growth is insane.Right now: 500K → 2M txns/day,$200M → $300M TVL.RWAs finally feel like they’re clicking.This might actually be the RWAfi moment. https://t.co/GHLn44b4gT ...

综合市场分析来看，金融科技回调下挫或与香港稳定币牌照落地不及预期有关。消息面上，香港《稳定 币条例》将于8月1日实施，7月29日下午，香港金管局披露了稳定币发行人相关监管制度。其中提到， 截至目前，尚未发出任何稳定币发行人牌照，未来将在官网公布获发牌照的稳定币发行人名单。 中信证券解读称，时间线上看，金管局鼓励意向申请人于8月31日前联系监管，成熟申请人申请时限为9 月30日，首批牌照张数仅个位数，预计有望于年底前落地。建议继续关注可能获取首批稀缺牌照的发行 人，及确定性参与稳定币使用场景创设的场景平台两条主线。 周三（7月30日），稳定币、跨境支付等热门题材悉数调整，高位人气股下挫，金融科技板块深度回 调，成份股大面积飘绿。其中，东信和平跌停，天阳科技、四方精创、恒宝股份均下挫超7%，长亮科 技、金证股股份、中科金财、拉卡拉、京北方、中亦科技等跟跌超5%。 热门ETF方面，规模、流动性同类断层第一的金融科技ETF（159851）放量下挫，场内价格收跌3.3%， 跌穿5日、10日均线，退守20日均线。全天成交额达12.75亿元，环比放量超五成！资金逢跌大举揽筹， 159851全天净申购达4.38亿份！ 数据来 ...

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase of over 16% following the announcement of a successful multi-billion yuan revolving loan obtained by its subsidiary, Weishida, from a banking syndicate led by East Asia Bank's Shanghai branch [1] Group 1: Financial Developments - The revolving loan involves participation from seven financial institutions, including Mitsui Sumitomo, Shengjing Bank, and Busan Bank of Korea [1] - The stock price rose by 16.31%, reaching HKD 4.35, with a trading volume of HKD 15.16 million [1] Group 2: Strategic Initiatives - On July 17, the company announced the establishment of the "IVDNewCo Exchange," a Web3 ecosystem focused on high-tech medical innovation assets, along with the issuance of a proprietary stablecoin, IVD Dollar (IVDD) [1] - On July 20, Huajian Medical registered a wholly-owned subsidiary, IVD GROUP INC., in New York, and initiated the application for stablecoin licenses with the SEC and CFTC [1] Group 3: Market Positioning - The "IVDNewCo Exchange" aims to address significant pain points in the pharmaceutical industry, where new drug development typically takes 10 years and 80% of funding is spent in clinical stages, while ordinary investors are often excluded [1] - The company’s strategy involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates through RWA technology [1] - Huajian Medical aims to become the "Nasdaq + Uniswap" of the medical RWA sector, ensuring compliance while achieving decentralized liquidity, leveraging its first-mover advantage in a niche market [1]

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase of over 16% following the announcement of a successful multi-billion yuan revolving loan obtained by its subsidiary, Weida [1] Group 1: Financial Developments - On July 29, Huajian Medical announced that its subsidiary Weida secured a multi-billion yuan revolving loan, led by the Shanghai branch of East Asia Bank, with participation from seven financial institutions including Sumitomo Mitsui, Shengjing Bank, and Busan Bank [1] - As of the report, the stock price rose by 16.31%, reaching HKD 4.35, with a trading volume of HKD 15.16 million [1] Group 2: Strategic Initiatives - On July 17, the company announced the establishment of the "IVDNewCo Exchange," a Web3 trading ecosystem focused on high-tech medical innovation assets, along with the issuance of a proprietary stablecoin, IVD Dollar (IVDD) [1] - On July 20, Huajian Medical registered a wholly-owned subsidiary, IVD GROUP INC., in New York, and initiated the application for stablecoin licenses with the SEC and CFTC [1] Group 3: Market Positioning - The "IVDNewCo Exchange" aims to address significant pain points in the pharmaceutical industry, where new drug development typically takes 10 years and 80% of funding is spent in clinical stages, while ordinary investors are often excluded [1] - The company’s strategy involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates through RWA technology [1] - Huajian Medical aims to become the "Nasdaq + Uniswap" in the medical RWA sector, ensuring compliance while achieving decentralized liquidity, leveraging its first-mover advantage in a niche market [1]

7月29日，华检医疗(01931)发布公告——子公司威士达成功获得一笔数亿元循环贷款。这笔由东亚银行上海分行牵头，三井住友、盛京银行、韩国釜山银行 等7家金融机构组成的银团共同参与的贷款，在当下信贷紧缩的环境下显得格外珍贵。贷款获批不仅是对子公司经营能力的认可，更是国际资本对华检医疗 未来战略的押注。 一、监管破冰：全球稳定币合规竞赛鸣枪起跑 8月1日，香港《稳定币条例》即将生效。这标志着全球三大金融中心全部完成稳定币立法布局：欧盟MiCA法案去年底生效，美国《天才法案》7月18日由 特朗普签署。监管铁幕落下，野蛮生长时代终结，合规竞赛正式鸣枪。 香港金管局对此态度鲜明。助理总裁何汉杰直言："先严、走稳，再适度放松。"监管层对牌照发放极为谨慎，首批仅计划发放"极少数"牌照。数十家跃跃欲 试的机构中，仅渣打、京东旗下JD Coinlink等沙盒参与者或获优先审核——但"优先权不保证获批"。 华检医疗7月30日公告 时间点耐人寻味。就在两天后的8月1日，香港《稳定币条例》将正式生效。而在过去半个月，华检医疗股价经历了一场过山车：7月14日至21日累计暴涨 75%，创下4.66港元历史新高;7月23日—28日，公司 ...

Regulatory Framework - The Hong Kong Monetary Authority (HKMA) has released regulatory documents for stablecoin issuance, detailing applicant qualifications, application processes, reserve asset requirements, anti-money laundering measures, and a transition period for existing issuers[2][7]. - The regulatory documents supplement the "Stablecoin Ordinance" effective from August 1, 2025, aiming to refine the licensing process and subsequent supervision of stablecoin issuers[7]. Application Requirements - Applicants must be registered corporations in Hong Kong with a minimum paid-up capital of HKD 25 million (approximately USD 3.2 million) or equivalent in freely convertible currency[7][8]. - The application process includes consultations with the HKMA and relevant regulatory bodies, submission of applications, and processing of applications[7]. Reserve Asset Guidelines - Licensed issuers must ensure that reserve assets fully back the stablecoins, which can include cash, bank deposits with a maturity of no more than 3 months, and high-liquidity bonds with a maturity of no more than 1 year[4][7]. - If using currencies other than the reference currency for stablecoins, prior written approval from the HKMA is required[4]. Anti-Money Laundering Measures - Issuers are required to continuously monitor transactions involving customer wallets, including both custodial and non-custodial wallets, to prevent money laundering and terrorist financing risks[4][7]. Transition Period for Existing Issuers - Existing issuers wishing to apply for a license must do so by October 31, 2025, at the latest[4][7]. Market Implications - The issuance of stablecoin licenses is expected to benefit companies with relevant applications, particularly in cross-border payments[8]. - The HKMA anticipates that only a limited number of licenses will be granted initially, prioritizing companies with applicable use cases[8]. Investment Recommendations - Companies with a strong presence in payment solutions, such as LianLian Digital, Lakala, and Yika, are recommended for investment due to their potential benefits from stablecoin licensing[8][9]. - The report highlights the importance of companies accelerating their engagement in real-world asset (RWA) scenarios, such as Linklogis and Jiufang Zhitu Holdings[8]. Risks - Potential risks include slower-than-expected regulatory progress and increased competition within the stablecoin industry[8].

（央链直播报道）2025 年 7 月 30 日时，全球 RWA 数据产业大会在香港数码港会议大厅启幕。参会嘉宾陆续签到入场，为这场聚焦 RWA 数据产业生态的 行业盛会预热。 中国移动通信联合会创始人兼执行会长、中国移动通信联合会人工智能与元宇宙产业委共同主席、中国移动通信联合会数智文教分会共同会长、全球元宇宙 大会发起人兼主席、香港RWA全球产业联盟名誉主席 倪健中 霍英东基金永远董事、RWA研究院名誉主席 霍振宇 香港专业及资深行政人员协会创会会长、全国政协经济委员会副主任 容永祺 香港原立法会议员、联交所 副主席、黄金交易所永远名誉会长、香港 东盟经济 合作基金会 副会长 冯志坚 香港城市大学 副监督、十三届 全国政协委员、原特区政府 行政会议 成员、摩根怡富 中国主席 钟瑞明 长远控股 董事局主席、MINAX创始人、执行主席 刘小鹰 MINAX交易所CEO 邓迪 富通资本 投资管理 有限公司 董事长、全国人大代表、港岛 各界联合会 会长 蔡毅 中国计算机学会 区块链专委会 荣誉主任、科技部"十四五" 区块链 重点专项专家组 组长 斯雪明 中国通信工业协会区块链专业委员会、中国移动通信联合会人工智能与元 ...